13F reference period
Q2 2026
Security Snapshot
Jade Biosciences, Inc. - Common Stock, par value $0.0001 per share (JBIO) Institutional Ownership
CUSIP: 008064206
13F Institutional Holders and Ownership History from Q2 2025 to Q3 2026
Institutions Reporting
150
Shares (Excl. Options)
72.9M
Full value: 72,902,699 · shares · 30 Jun 2026Price
$22.22
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- JBIO on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 72,902,699
- Total 13F value
- $1,619,316,966
- Portfolio coverage rank
- 0%
- Share change
- +19,717,761
- Value change
- +$459,525,093
- Number of holders
- 150
- Shares outstanding
- 63,453,933
- SEC-reported price per share
- $13.42
- Insider filing price
- $13.42
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- JBIO - Jade Biosciences, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 008064206.
- 150 institutions reported positions in Q2 2026.
- 14 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 118 to 150 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$700.29M
Full value: $700,290,229 · USD · 31 Mar 2026.$1.62B
Full value: $1,619,316,966 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 150 institutions filings for Q2 2026.
Security key
008064206
13F reference period
Q2 2026
13F holders
150
13D/G owners
14
CIK / CUSIP context first
Open Q2 2026 holders
JBIO full holder history
Jade Biosciences, Inc. SEC filings
Jade Biosciences, Inc. company facts
Jade Biosciences, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 008064206:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
14
Security
JBIO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 20% | 0% | $354,973,334 | +$93,745,067 | 14,069,494 | +36% | Fairmount Funds Management LLC | 05 Jun 2026 |
| Janus Henderson Group Ltd. | 11% | +72% | $139,393,136 | +$70,384,550 | 6,273,262 | +102% | JANUS HENDERSON GROUP Ltd. | 30 Jun 2026 |
| Venrock Healthcare Capital Partners III, L.P. | 8.3% | -16% | $107,794,664 | +$617,355 | 5,145,330 | +0.58% | Venrock Healthcare Capital Partners III, L.P. | 30 Jun 2026 |
| FMR LLC | 15% | $40,965,976 | 4,735,951 | FMR LLC | 30 May 2025 | |||
| FRANKLIN TEMPLETON INC | 6% | $53,491,285 | 3,807,236 | Franklin Templeton, Inc. | 30 Sep 2026 | |||
| BlackRock, Inc. | 5.2% | +10% | $46,692,047 | +$14,435,935 | 3,323,301 | +45% | BlackRock, Inc. | 30 Sep 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 7% | +72% | $27,758,364 | +$16,318,579 | 3,214,969 | +143% | RA Capital Management, L.P. | 08 Oct 2025 |
| Paradigm Biocapital Advisors LP | 5.1% | $69,032,630 | 3,106,793 | Paradigm BioCapital Advisors LP | 10 Jul 2026 | |||
| Bellevue Group AG | 5% | -26% | $64,065,016 | -$5,931,092 | 3,057,996 | -8.5% | Bellevue Group AG | 30 Jun 2026 |
| VANGUARD GROUP INC | 4.2% | -23% | $32,337,685 | +$4,446,695 | 2,095,767 | +16% | The Vanguard Group | 31 Dec 2025 |
| Frazier Life Sciences Public Fund, L.P. | 4.2% | 0% | $11,949,495 | +$379,228 | 1,384,646 | +3.3% | Frazier Life Sciences Public Fund, L.P. | 30 Sep 2025 |
| Sofinnova Venture Partners X, L.P. | 0.3% | $1,617,308 | 107,391 | Sofinnova Venture Partners X, L.P. ("SVP X") | 28 Apr 2025 | |||
| TCG Crossover GP I, LLC | 0.2% | $649,193 | 64,023 | TCG Crossover GP I, LLC | 28 Apr 2025 | |||
| Atlas Venture Fund XII, L.P. | 0.2% | $521,257 | 51,406 | Atlas Venture Associates XII, L.P. | 28 Apr 2025 |
As of 30 Jun 2026,
150
institutional investors reported holding
shares of
Jade Biosciences, Inc. - Common Stock, par value $0.0001 per share (JBIO).
This represents
115%
of the company’s total
outstanding shares.
72.9M
Full value: 72,902,699 · shares · 30 Jun 202663.45M
Full value: 63,453,933 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
96%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 14% | 9,126,877 | +29% | 0.01% | $202,799,207 |
| Jupiter Topco LLC | 9.9% | 6,273,262 | 0% | 0.06% | $139,369,006 |
| Fairmount Funds Management LLC | 7.2% | 4,553,494 | 0% | 6.7% | $101,178,637 |
| RA CAPITAL MANAGEMENT, L.P. | 5.8% | 3,671,083 | 0% | 0.71% | $81,571,464 |
| Venrock Adviser, LLC | 5.1% | 3,220,364 | 0% | 2.2% | $71,556,488 |
| Bellevue Group AG | 4.8% | 3,057,996 | -13% | 1.4% | $67,948,671 |
| Paradigm Biocapital Advisors LP | 4.5% | 2,857,405 | 1.2% | $63,491,539 | |
| BlackRock, Inc. | 4.4% | 2,801,451 | +21% | 0% | $62,248,241 |
| FRANKLIN RESOURCES INC | 4.4% | 2,792,080 | 0.01% | $62,040,028 | |
| STATE STREET CORP | 3.7% | 2,335,285 | +256% | 0% | $51,890,033 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.5% | 2,244,773 | +25% | 0% | $49,878,856 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3% | 1,910,812 | 0.06% | $42,458,243 | |
| Polar Capital Holdings Plc | 2.9% | 1,846,982 | 0.12% | $41,039,940 | |
| Avidity Partners Management LP | 2.7% | 1,700,708 | +21% | 6.1% | $37,789,732 |
| Remedium Capital Partners, LLC | 2.5% | 1,577,750 | 0% | 7.8% | $35,057,605 |
| Soleus Capital Management, L.P. | 2.4% | 1,550,690 | +95% | 1.2% | $34,456,332 |
| JPMORGAN CHASE & CO | 2.3% | 1,475,079 | +9199% | 0% | $32,613,997 |
| BAKER BROS. ADVISORS LP | 1.9% | 1,230,426 | -25% | 0.14% | $27,340,066 |
| Logos Global Management LP | 1.8% | 1,125,000 | +181% | 1.1% | $24,997,500 |
| Versant Venture Management, LLC | 1.6% | 991,783 | -35% | 14% | $22,037,418 |
| ACORN CAPITAL ADVISORS, LLC | 1.6% | 986,760 | +25% | 6% | $21,925,807 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6% | 985,178 | +20% | 0% | $21,896,658 |
| CITADEL ADVISORS LLC | 1.5% | 929,407 | +577% | 0.01% | $20,651,423 |
| Foresite Capital Management VI LLC | 1.4% | 886,667 | +177% | 3.1% | $19,701,741 |
| Balyasny Asset Management L.P. | 1.4% | 878,726 | +118% | 0.04% | $19,525,292 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
6
Headline period
Q2 2026
Rows shown
1-6 of 6
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 31,972 | $449,208 | -$196,331 | $14.05 | 17 |
| 2026 Q2 | 72,902,699 | $1,619,316,966 | +$459,525,093 | $22.22 | 150 |
| 2026 Q1 | 49,846,615 | $700,290,229 | +$35,560,462 | $14.05 | 118 |
| 2025 Q4 | 47,075,378 | $726,260,386 | +$242,240,917 | $15.43 | 102 |
| 2025 Q3 | 31,617,300 | $272,859,518 | +$407,366 | $8.63 | 74 |
| 2025 Q2 | 31,531,484 | $315,000,764 | +$314,968,047 | $9.99 | 70 |